홈 > 시장보고서 > 의료기기

시장보고서

상품코드

1606536

세계의 뇌척수액 션트 시스템 시장(2024-2031년)

Global Cerebral Spinal Fluid (CSF) Shunt Systems Market - 2024-2031

발행일: 2024년 12월 | 리서치사:

DataM Intelligence | 페이지 정보: 영문 176 Pages | 배송안내 : 1-2일 (영업일 기준)

■ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송일정은 문의해 주시기 바랍니다.

개요

세계의 뇌척수액 션트 시스템 시장은 2023년에 8억 9,420만 달러에 달하며, 2031년에는 13억 9,830만 달러에 달할 것으로 예측되며, 예측 기간 중 CAGR 5.8%로 성장할 전망입니다.

뇌척수액(CSF) 션트 시스템은 과도한 뇌척수액(CSF)을 뇌와 척수의 일부에서 신체의 다른 부위로 우회하도록 설계된 의료기기로, 일반적으로 수두증으로 알려진 CSF의 비정상적인 저류가 있을 때 사용됩니다. 뇌척수액 션트 시스템은 주로 뇌에 수액이 고여 두개 내압이 상승하여 뇌 조직을 손상시킬 수 있는 수두증 및 기타 질환을 치료하는 데 사용됩니다. 뇌척수액 션트 시스템은 뇌척수액의 비정상적인 저류와 관련된 상태를 관리하는 데 중요한 역할을 하며, 정상적인 뇌 기능을 유지하고 장기적인 신경학적 손상을 예방하는 데 도움이 됩니다.

뇌척수액 션트 시스템에 대한 세계 수요는 여러 요인에 의해 확대되고 있습니다. 특히 성인과 소아 인구에서 수두증, 외상성 뇌손상, 두개내압항진증과 같은 신경질환의 유병률이 증가하고 있는 것이 주요 요인입니다. 예를 들어 세계보건기구(WHO)에 따르면 2021년에는 전 세계 30억 명 이상이 신경질환을 앓고 있을 것으로 예상하고 있습니다. 보다 효과적인 션트 시스템, 덜 침습적인 시술 등 의료 기술의 발전이 시장 성장을 지원하고 있습니다.

예를 들어 UCLA 보건기구에 따르면 미국에서는 출생아 1,000명당 2명꼴로 수두증이 발생합니다. 출생 후 발병하는 사람의 수는 알 수 없습니다. 약 12만 5,000명이 뇌척수액(CSF) 션트 시스템을 사용하여 생활하고 있으며, 미국에서는 연간 3만 3,000개의 션트가 설치되고 있습니다.

시장 역학 :

촉진요인과 억제요인

수두증의 유병률 증가

수두증의 유병률 증가는 뇌수액 션트 시스템 시장의 성장을 크게 견인하고 있으며, 예측 기간 중에도 계속 이어질 것으로 예상됩니다. 수두증은 뇌에 뇌척수액이 비정상적으로 축적되어 두개 내압이 상승하고 치료하지 않으면 뇌 손상을 유발할 수 있는 질환입니다.

예를 들어 Medscape에 따르면 전 세계 수두증의 유병률은 10만 명당 약 85명으로 추정되며, 연령대별로 차이가 뚜렷해 소아는 10만 명당 88명, 성인은 10만 명당 11명인 것으로 나타났습니다. 또한 Neurology India에 따르면 수두증의 발생률은 중저소득 국가(LMIC)에서 출생아 10만 명당 123명인 반면, 고소득 국가에서는 79명인 것으로 나타났습니다. 선천성 수두증(선천성)과 후천성 수두증(외상, 감염, 종양으로 인한)의 유병률이 모두 증가하고 있으며, 이는 뇌수액 션트 시스템에 대한 수요에 직접적으로 기여하고 있습니다.

노년층에서 많이 발생하는 정상압수두증도 큰 요인입니다. 세계 인구의 고령화, 특히 선진국에서 정상압수두증 진단이 증가하고 있으며, 많은 경우 션트 치료가 필요합니다. 예를 들어 알츠하이머병 협회에 따르면 정상압수두증은 주로 60-70대에 발병합니다. 수두증 협회는 약 70만 명의 성인이 정상압수두증을 앓고 있는 것으로 추정하고 있습니다.

착상 후 합병증 발생 위험이 높습니다.

뇌척수액 션트 시스템 시장은 이식 후 합병증 위험이 높다는 점이 시장 성장을 저해하는 요인으로 작용할 것으로 예상됩니다. 이러한 합병증은 환자의 예후에 영향을 미칠 뿐만 아니라 추가 의료 비용, 치료 시간 증가, 션트 기술에 대한 환자 및 의료진의 신뢰도 저하로 이어집니다. 감염은 수액 션트 이식 후 가장 흔한 합병증 중 하나입니다.

예를 들어 ScienceDirect에 따르면 션트 감염률은 약 5-15%이며, 대부분의 감염은 상처의 오염에 기인합니다. 감염의 거의 70%는 피부 세균총 포도상구균에 의한 것입니다. 수액 션트 감염은 보통 삽입 후 2개월 이내에 발생합니다.

감염은 수막염이나 패혈증과 같은 심각한 합병증을 유발할 수 있으며, 션트 교체, 항생제 및 재수술과 같은 집중 치료를 받아야 합니다. 재수술의 필요성은 전체 의료 비용을 증가시키고 션트 시스템의 장기적인 생존에 영향을 미쳐 시장 수용을 제한합니다.

이 보고서에 대한 자세한 내용-샘플 요청

Cerebrospinal Fluid (CSF) shunt systems are medical devices designed to divert excess cerebrospinal fluid (CSF) from one part of the brain or spinal cord to another area of the body, typically when there is an abnormal accumulation of CSF, a condition known as hydrocephalus. These systems are primarily used to treat hydrocephalus and other conditions that cause fluid buildup in the brain, which can lead to increased intracranial pressure, potentially damaging brain tissue. CSF shunt systems play a crucial role in managing conditions related to abnormal CSF buildup, helping to maintain normal brain function and prevent long-term neurological damage.

The global demand for cerebral spinal fluid shunt systems is growing due to several factors. A key driver is the increasing prevalence of neurological disorders such as hydrocephalus, traumatic brain injuries and intracranial hypertension, particularly among both the adult and pediatric populations. For instance, according to the WHO, in 2021, more than 3 billion people worldwide were living with a neurological condition. Advances in medical technologies, including more effective shunting systems and less invasive procedures, support market growth.

For instance, according to the UCLA Health Organization, hydrocephalus occurs in two out of every 1,000 births in the United States. It is not known how many people develop it after birth. Approximately 125,000 persons are living with cerebrospinal fluid (CSF) shunt systems and 33,000 shunts are placed annually in the United States.

Market Dynamics: Drivers & Restraints

Rising prevalence of hydrocephalus

The rising prevalence of hydrocephalus is significantly driving the growth of the spinal fluid shunt systems market and is expected to drive over the forecast period. Hydrocephalus, a condition characterized by the abnormal accumulation of cerebrospinal fluid in the brain, leads to increased intracranial pressure, potentially causing brain damage if untreated.

For instance, according to Medscape, the global prevalence of hydrocephalus is estimated at approximately 85 cases per 100,000 individuals, with notable variation across age groups, 88 per 100,000 in the pediatric population and 11 per 100,000 in adults. Additionally, according to Neurology India, the incidence of hydrocephalus is 123 per 100,000 births in low- and middle-income countries (LMICs) compared to 79 per 100,000 births in high-income countries. The prevalence of both congenital hydrocephalus (present from birth) and acquired hydrocephalus (due to trauma, infections, or tumors) is increasing, contributing directly to the demand for CSF shunt systems.

Normal pressure hydrocephalus, common among the elderly, is another major factor. The aging global population, particularly in developed countries, is leading to more diagnoses of normal pressure hydrocephalus, which often requires shunt intervention. For instance, according to the Alzheimer's Association, normal pressure hydrocephalus primarily affects people in their 60s and 70s. The Hydrocephalus Association estimates that nearly 700,000 adults have normal-pressure hydrocephalus

High risk of post-implantation complications

The high risk of post-implantation complications is expected to hamper the cerebral spinal fluid shunt systems market. These complications not only affect patient outcomes but also lead to additional healthcare costs, increased treatment time and a decrease in patient and provider confidence in shunt technologies. Infections are one of the most common complications after CSF shunt implantation.

For instance, according to ScienceDirect, shunt infection rates range from about 5% to 15%, with most infections resulting from wound contamination. Almost 70% of infections are caused by skin flora staphylococcal organisms. CSF shunt infections usually occur within 2 months after implantation.

Infections can lead to serious complications such as meningitis or sepsis, requiring the shunt to be replaced and the patient to undergo intensive treatment, including antibiotics or even re-surgery. The need for repeated surgeries increases the overall healthcare costs and impacts the long-term viability of shunt systems, limiting their market acceptance.

For more details on this report - Request for Sample

Segment Analysis

The global cerebral spinal fluid shunt systems market is segmented based on product type, material, valve type, indication, age group, end-user and region.

Indication:

The ventriculoperitoneal shunts segment is expected to dominate the global cerebral spinal fluid shunt systems market share

The ventriculoperitoneal shunts segment holds a major portion of the cerebral spinal fluid shunt systems market share and is expected to continue to hold a significant portion of the market share over the forecast period due to their widespread use, effectiveness and cost-efficiency in treating hydrocephalus, particularly in pediatric patients. These shunts are preferred for their ability to effectively redirect excess cerebrospinal fluid from the brain's ventricles to the peritoneal cavity (abdomen), where the fluid can be absorbed into the bloodstream.

Thus, due to the wide advantages offered by ventriculoperitoneal shunts, many major and emerging market players are focussing on these stunts. For instance, in May 2024, CereVasc, Inc. approval from the US Food and Drug Administration (FDA) to initiate its "Pivotal Study to Evaluate the Safety and Effectiveness of the CereVasc eShunt System in the Treatment of Normal Pressure Hydrocephalus" (STRIDE trial). The STRIDE pivotal study compares the safety and efficacy of its novel eShunt System for the treatment of patients with Normal Pressure Hydrocephalus to treatment with the current standard of care, the ventriculoperitoneal (VP) shunt.

Ventriculoperitoneal shunts are considered the gold standard in treating hydrocephalus, especially in congenital cases. This widespread use in both pediatric and adult populations significantly contributes to their market dominance. Ventriculoperitoneal shunts are highly effective in the long-term management of hydrocephalus, with studies showing that they are successful in reducing symptoms and improving patient outcomes, especially when timely intervention is applied.

North America is expected to hold a significant position in the global cerebral spinal fluid shunt systems market

North America region is expected to hold the largest market share over the forecast period. North America, especially the United States has a high prevalence of hydrocephalus, a major condition treated by CSF shunt systems. According to the Hydrocephalus Association, around 1 in 500 to 1,000 live births are affected by congenital hydrocephalus in the United States, leading to a significant demand for shunt devices.

North America is home to the most advanced shunt technologies. Companies in the region have pioneered the development of programmable shunts and anti-siphon devices, which offer better control over cerebrospinal fluid flow and minimize the risk of complications such as infection or over-drainage. These innovations enhance patient outcomes and make CSF shunt systems more effective, leading to greater adoption and market share.

For instance, in August 2024, Aesculap, Inc. (Aesculap), in partnership with Christoph Miethke GmbH & Co. KG (MIETHKE), cleared that the U.S. Food and Drug Administration (FDA) granted Breakthrough Device Designation for the M.scio System. This unique, non-invasive, telemetric pressure measurement system is designed to provide continuous access to long-term, intracranial pressure (ICP) monitoring of cerebrospinal fluid (CSF) for the management of hydrocephalus via a permanent, fully implantable sensor.

Asia Pacific is growing at the fastest pace in the cerebral spinal fluid shunt systems market

The Asia Pacific region is experiencing the fastest growth in the cerebral spinal fluid shunt systems market. The prevalence of hydrocephalus and other neurological disorders is rising in the Asia Pacific region. The incidence of congenital hydrocephalus in countries like India and China is on the rise, partly due to better survival rates among preterm infants and improvements in neonatal care. For example, India has seen an increase in congenital hydrocephalus diagnoses, with studies indicating a prevalence of about 0.6-1.2 per 1,000 live births.

Medical tourism is also contributing to the growth of the CSF shunt market in Asia Pacific. Countries like India, Thailand and Singapore are popular destinations for medical tourists seeking affordable and high-quality hydrocephalus treatment. For instance, according to the Ministry of Tourism, India has been ranked 10th in the Medical Tourism Index (MTI) for 2020-21 out of 46 destinations in the world by the Medical Tourism Association. The increase in medical tourism is partly due to the availability of skilled healthcare professionals and modern surgical facilities at relatively lower costs compared to Western countries.

Competitive Landscape

The major global players in the cerebral spinal fluid shunt systems market include Medtronic plc, Aesculap, Inc., Sophysa, Integra LifeSciences Corporation, Christoph Miethke GmbH & Co. KG, Delta Surgical, Anuncia Inc., Spiegelberg GmbH & Co. KG, HpBio, BIcakcIlar and among others.

Why Purchase the Report?

Pipeline & Innovations: Insights into clinical trials, product pipelines, and upcoming advancements.
Market Positioning: Analysis of product performance and growth potential for optimized strategies.
Real-World Evidence: Integration of patient feedback for enhanced product outcomes.
Physician Preferences: Insights into healthcare provider behaviors and adoption strategies.
Regulatory & Market Updates: Coverage of recent regulations, policies, and emerging technologies.
Competitive Insights: Analysis of market share, competitor strategies, and new entrants.
Pricing & Market Access: Review of pricing models, reimbursement trends, and access strategies.
Market Expansion: Strategies for entering new markets and forming partnerships.
Regional Opportunities: Identification of high-growth regions and investment prospects.
Supply Chain Optimization: Assessment of risks and distribution strategies.
Sustainability & Regulation: Focus on eco-friendly practices and regulatory changes.
Post-Market Surveillance: Enhanced safety and access through post-market data.
Value-Based Pricing: Insights into pharmacoeconomics and data-driven R&D decisions.

The global cerebral spinal fluid shunt systems market report delivers a detailed analysis with 86 key tables, more than 85 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2023

Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
Supply Chain: Distribution and Supply Chain Managers.
Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
Academic & Research: Academic Institutions.

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Product Type
3.2. Snippet by Material
3.3. Snippet by Valve Type
3.4. Snippet by Indication
3.5. Snippet by Age-Group
3.6. Snippet by End-User
3.7. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Rising Prevalence of Hydrocephalus
  - 4.1.1.2. Technological Advancements in Stunt Systems
- 4.1.2. Restraints
  - 4.1.2.1. High Risk of Post-Implantation Complications
- 4.1.3. Opportunity
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Patent Analysis
5.5. Regulatory Analysis
5.6. SWOT Analysis
5.7. Unmet Needs

6. By Product Type

6.1. Introduction
- 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 6.1.2. Market Attractiveness Index, By Product Type
6.2. Ventriculoperitoneal Shunts*
- 6.2.1. Introduction
- 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Ventriculoatrial Shunts
6.4. Lumboperitoneal Shunts
6.5. Ventriculopleural Shunts
6.6. Others

7. By Material

7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material
- 7.1.2. Market Attractiveness Index, By Material
7.2. Silicone-based Shunts*
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Polymer-based Shunts
7.4. Metal-based Shunts

8. By Valve Type

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Valve Type
- 8.1.2. Market Attractiveness Index, By Valve Type
8.2. Fixed Pressure Valves*
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Adjustable Pressure Valves

9. By Indication

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
- 9.1.2. Market Attractiveness Index, By Indication
9.2. Congenital Hydrocephalus*
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Acquired Hydrocephalus
9.4. Post-Surgical Hydrocephalus
9.5. Others

10. By Age Group

10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
- 10.1.2. Market Attractiveness Index, By Age Group
10.2. Pediatrics*
- 10.2.1. Introduction
- 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Adults
10.4. Geriatrics

11. By End-User

11.1. Introduction
- 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 11.1.2. Market Attractiveness Index, By End-User
11.2. Hospitals*
- 11.2.1. Introduction
- 11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
11.3. Specialty Clinics
11.4. Ambulatory Surgical Centers
11.5. Others

12. By Region

12.1. Introduction
- 12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 12.1.2. Market Attractiveness Index, By Region
12.2. North America
- 12.2.1. Introduction
- 12.2.2. Key Region-Specific Dynamics
- 12.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 12.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material
- 12.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Valve Type
- 12.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
- 12.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
- 12.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 12.2.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 12.2.9.1. U.S.
  - 12.2.9.2. Canada
  - 12.2.9.3. Mexico
12.3. Europe
- 12.3.1. Introduction
- 12.3.2. Key Region-Specific Dynamics
- 12.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 12.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material
- 12.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Valve Type
- 12.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
- 12.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
- 12.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 12.3.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 12.3.9.1. Germany
  - 12.3.9.2. U.K.
  - 12.3.9.3. France
  - 12.3.9.4. Spain
  - 12.3.9.5. Italy
  - 12.3.9.6. Rest of Europe
12.4. South America
- 12.4.1. Introduction
- 12.4.2. Key Region-Specific Dynamics
- 12.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 12.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material
- 12.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Valve Type
- 12.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
- 12.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
- 12.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 12.4.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 12.4.9.1. Brazil
  - 12.4.9.2. Argentina
  - 12.4.9.3. Rest of South America
12.5. Asia-Pacific
- 12.5.1. Introduction
- 12.5.2. Key Region-Specific Dynamics
- 12.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 12.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material
- 12.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Valve Type
- 12.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
- 12.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
- 12.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 12.5.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 12.5.9.1. China
  - 12.5.9.2. India
  - 12.5.9.3. Japan
  - 12.5.9.4. South Korea
  - 12.5.9.5. Rest of Asia-Pacific
12.6. Middle East and Africa
- 12.6.1. Introduction
- 12.6.2. Key Region-Specific Dynamics
- 12.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 12.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material
- 12.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Valve Type
- 12.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
- 12.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
- 12.6.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

13. Competitive Landscape

13.1. Competitive Scenario
13.2. Market Positioning/Share Analysis
13.3. Mergers and Acquisitions Analysis

14. Company Profiles

14.1. Medtronic plc*
- 14.1.1. Company Overview
- 14.1.2. Product Portfolio and Description
- 14.1.3. Financial Overview
- 14.1.4. Key Developments
14.2. Aesculap, Inc.
14.3. Sophysa
14.4. Integra LifeSciences Corporation
14.5. Christoph Miethke GmbH & Co. KG
14.6. Delta Surgical
14.7. Anuncia Inc.
14.8. Spiegelberg GmbH & Co. KG
14.9. HpBio
14.10. BIcakcIlar (LIST NOT EXHAUSTIVE)

15. Appendix

15.1. About Us and Services
15.2. Contact Us

02-2025-2992
(주말 및 공휴일 제외)

라이선스 / 가격

PDF & Excel (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 4,350

￦ 6,294,000

PDF & Excel (Multiple User License)

PDF 보고서를 동일 사업장에서 7명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 4,850

￦ 7,017,000

PDF & Excel (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 7,850

￦ 11,358,000

※ 부가세 별도

세계의 뇌척수액 션트 시스템 시장(2024-2031년)

Global Cerebral Spinal Fluid (CSF) Shunt Systems Market - 2024-2031

시장 역학 :

목차

제1장 조사 방법과 조사 범위

제2장 정의와 개요

제3장 개요

제4장 시장 역학

제5장 산업 분석

제6장 제품 유형별

제7장 재료별

제8장 밸브 유형별

제9장 적응증별

제10장 연령층별

제11장 최종사용자별

제12장 지역별

제13장 경쟁 구도

제14장 기업 개요

제15장 부록